Publikationen, an denen er mitarbeitet ISMAEL BUÑO BORDE (68)

2024

  1. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

    Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12

  2. Identification of predictive models including polymorphisms in cytokines genes and clinical variables associated with post-transplant complications after identical HLA-allogeneic stem cell transplantation

    Frontiers in Immunology, Vol. 15

2023

  1. Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 472.e1-472.e4

  2. Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing

    Cancers, Vol. 15, Núm. 3

  3. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567

  4. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

2022

  1. Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy

    Transfusion, Vol. 62, Núm. 10, pp. 2143-2147

  2. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation

    Frontiers in immunology, Vol. 13, pp. 1002959

  3. Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment (BMC Cancer, (2022), 22, 1, (982), 10.1186/s12885-022-10070-z)

    BMC Cancer

  4. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

    BMC Cancer, Vol. 22, Núm. 1

  5. FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 16

  6. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms

    Annals of Hematology, Vol. 101, Núm. 7, pp. 1567-1576

2021

  1. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  2. Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2273-2284

  3. Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  4. Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 62, Núm. 5, pp. 1178-1186

  5. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma

    Cancer Medicine, Vol. 10, Núm. 21, pp. 7585-7592

  6. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma

    Scientific Reports, Vol. 11, Núm. 1

  7. Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations

    Cancers, Vol. 13, Núm. 12

  8. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553